IMI - Call 16: Projects on Tuberculosis (TB) and Antimicrobial resistance (AMR)
IMI-2 (Innovative medicines initiative) has launched seven topics for projects to advance the RnD pipeline of new and innovative agents to address AMR. Deadline is October 24th, 2018.
- Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
- Available funding: 6,8 M€. Indicative duration: 72 months.
- Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
- Available funding: 5,7 M€. Indicative duration: 72 months.
- Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
- Available funding: 1,8 M€. Indicative duration: 72 months.
- Determination of gepotidacin levels in tonsils and prostatic tissue
- Available funding: 7,3 M€. Indicative duration: 18 months.
- Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
- Available funding: 6 M€. Indicative duration: 36 months.
- Functional Ethionamide boosters: a novel combination for tuberculosis therapy
- Available funding: 7 M€. Indicative duration: 48 months.
- Intravenous treatments of serious infections (urinary tract infections (UTI), intra-abdominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
- Available funding: 12,3 M€. Indicative duration: 72 months.
A webinar explaining the topics was conducted July 6th. Click to see presentations, recording and list of participants.
Applicant consortia must include at least two independent legal entities established in different EU member states or associated countries of which one must be an EFPIA Company.